DELHI, India, Sept. 23, 2020 (GLOBE NEWSWIRE) -- "Global Cancer Generics Market, Drug Dosage, Price & Opportunity Insight 2026" Report Highlights:
- Global Cancer Generics Market Trend Analysis
- Global Cancer Generics Market Opportunity: > USD 55 Billion By 2026
- Global Generics Market Growth 2018-2026: > 130%
- Global Cancer Generics Market Growth 2018-2026: 200%
- Reimbursement Policies & the Coverage Strategies By Countries
- Cancer Generic Drugs Availability, Dosage & Price Analysis By Segment
- Comprehensive Insight On Cancer Generics Drugs: 43 Generics
Download Report:
https://www.kuickresearch.com/report-global-cancer-generics-market,-drug-dosage,-price-and-opportunity-insight-2026.php
Treatment for a specific solid cancer is limited by affordability of patients in several different developing countries in the world such as India, Middle East and Africa. To overcome this, generic drug manufacturers all over the world have responded to this challenge by developing the drugs that are bioequivalent to the branded cancer drugs but at an affordable price, which is mostly 40-50% less than the cost of the branded drug. As per the analysis conducted by the research team, the prescription filled for the cancer generics drugs is way more than the prescription filled for the branded drug, which is now accompanied by cost savings strategies by the patients as well as the government in importing generics drugs from other markets to unmeet the needs of the local cancer population.
Fortunately, the importance of cancer generics drugs in the pharmaceutical market has taken a leap as the regulatory environment in all the major markets having generic drug makers are now geared to ensure the continuous development of the generic drugs with complete bio-equivalence and mechanism as per branded drugs. Some of the markets that are dedicated for developing the cancer generics drugs for the patients have set the standards for regulatory agencies that allow the emergence of specific cancer generics without undergoing long clinical evaluation. The ANDA filling by the drug maker and fast end regulatory check for the drugs is estimated to be the only proposal for making the drug enter the market. This step is also however joined by the emergence of several novel entrants interested in developing cancer generic drugs.
Over the past few years, cancer generics have gained and remained successful in achieving traction in the overall cancer therapeutics industry. With more than a revenue of US$ 23 Billion by the end of the year 2019, the market is witnessed to dominate the branded drugs to much extent. By the end of the year 2026 it is estimated that the market will generate more than US$ 55 Billion in revenue and comprise more than 40% of the overall cancer therapeutics market. An important factor that is driving the revenue generation for the market is the balance that has been created by the US FDA regarding the availability of the cancer generics for developed as well as under-developed markets of the world.
The analysis of the market with respect to growing market shifts and increase in the revenue within a short period is estimated to be the result of the increase in the total number of enterprises that believe in developing the drugs without spending billions of dollars in the research and development process of the cancer drugs as done by the parent company of a respective branded cancer drug. In the next few years, the market is estimated to expand in terms of generic products available in the pipeline as well as the entrants interested in the market. Considerable opportunities exist in the emerged markets of cancer generics, leading to a massive attraction of the major key players, researchers and patients towards the market.
Table of Contents
1. Introduction to Cancer Generics
2. Global Cancer Generics Market Trend Analysis
3. US - Current Market Status of Cancer Generics
4. Japan - Current Cancer Generics Market Insight
5. Europe - Key Asset to Cancer Generics Market Progression
6. China - As a Emerged Cancer Generic Market in Asia
7. India - A Major Contributor to the Global Generics Market
8. South Korea - Cancer Generics Market Current Insight
9. Russia - Cancer Generics Market Scenario
10. Reimbursement Policies & the Coverage Strategies
11. Price Analysis for Branded Drugs VS Generic Drugs
12. Breast Cancer Generic Drugs - Availability, Dosage & Price Analysis
13. Colorectal Cancer Generic Drugs - Availability, Dosage & Price Analysis
14. Leukemia Generic Drugs - Availability, Dosage & Price Analysis
15. Prostate Cancer Generic Drugs - Availability, Dosage & Price Analysis
16. Skin Cancer Generic Drugs - Availability, Dosage & Price Analysis
17. Lung Cancer Generic Drugs - Availability, Dosage & Price Analysis
18. Brain Tumor Generic Drugs - Availability, Dosage & Price Analysis
19. Renal Cell Carcinoma Generic Drug - Availability, Dosage & Price Analysis
20. Generic Drugs for Multiple Cancers - Availability, Dosage & Price Analysis
21. Global Cancer Generics Market Dynamics
22. Competitive Landscape
Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-9810410366